Oculis Holding AG
OCS
View Detailed Chart
20.690USD
+0.210+1.03%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.03%
5 Days
+6.48%
1 Month
+7.26%
6 Months
+4.76%
Year to Date
+21.71%
1 Year
+21.78%
View Detailed Chart
TradingKey Stock Score of Oculis Holding AG
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Oculis Holding AG's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
44.111
Target Price
+114.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Oculis Holding AG Highlights
StrengthsRisks
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -7.34, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 16.41M shares, increasing 4.89% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 2.05K shares of this stock.
Oculis Holding AG News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Oculis Holding AG Info
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Ticker SymbolOCS
CompanyOculis Holding AG
CEOSherif (Riad)
Websitehttps://oculis.com/
FAQs
What is the current price of Oculis Holding AG (OCS)?
The current price of Oculis Holding AG (OCS) is 20.690.
What is the symbol of Oculis Holding AG?
The ticker symbol of Oculis Holding AG is OCS.
What is the 52-week high of Oculis Holding AG?
The 52-week high of Oculis Holding AG is 23.080.
What is the 52-week low of Oculis Holding AG?
The 52-week low of Oculis Holding AG is 14.000.
What is the market capitalization of Oculis Holding AG?
The market capitalization of Oculis Holding AG is 1.16B.
What is the net income of Oculis Holding AG?
The net income of Oculis Holding AG is -85.78M.
Is Oculis Holding AG (OCS) currently rated as Buy, Hold, or Sell?
According to analysts, Oculis Holding AG (OCS) has an overall rating of --, with a price target of 44.111.
What is the Earnings Per Share (EPS TTM) of Oculis Holding AG (OCS)?
The Earnings Per Share (EPS TTM) of Oculis Holding AG (OCS) is -2.716.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
